Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Parathyroid Disease Treatment Market Revenue Growth Supported By A CAGR Of 3.31% Through 2030
Over the past several years, the market for treatments addressing parathyroid disease has demonstrated robust growth, with projections indicating an increase from $2.37 billion in 2025 to $2.54 billion in 2026, reflecting a compound annual growth rate (CAGR) of 7.2%. This expansion during the historical period is largely driven by a growing incidence of hyperparathyroidism, insufficient public understanding of parathyroid conditions, reliance on traditional hormone replacement therapies, limited availability of sophisticated surgical options, and underdeveloped hospital pharmacy systems.
The market for parathyroid disease treatment is projected to experience significant expansion over the coming years. By 2030, it is anticipated to reach a value of $3.31 billion, reflecting a compound annual growth rate (CAGR) of 6.8%. This forecasted growth is driven by rising demand for calcimimetics and bisphosphonates, progress in parathyroid imaging and diagnostic techniques, the expansion of homecare and telemedicine services, regulatory backing for precision medicine, and the development of specialized endocrine disorder centers. Key trends expected to shape the market include the growing use of calcimimetics and bisphosphonates, a shift toward parenteral delivery over oral options in severe cases, the broadening of hospital and specialty care facilities, increased emphasis on customized hormone replacement therapies, and the inclusion of lifestyle and nutritional strategies in treatment protocols.
Download A Free Sample Report For Comprehensive Market Insights:
Parathyroid Disease Treatment Market Demand Drivers Creating New Revenue Opportunities
The growing frequency of chronic kidney disease (CKD) is anticipated to boost the expansion of the parathyroid disease treatment market in the coming period. As a long-term disorder, chronic kidney disease involves a progressive decline in kidney function, which triggers disruptions in mineral levels like calcium and phosphorus. This rise in CKD cases is largely driven by the increasing occurrence of diabetes, since sustained high blood glucose can gradually impair the kidneys’ filtering structures, resulting in diabetic nephropathy. Treatment for parathyroid disease becomes critical in managing CKD, particularly by addressing secondary hyperparathyroidism—a common issue in advanced stages that alters calcium and phosphorus balance, leads to bone disorders, and fosters vascular calcification. By May 2024, data from the Centers for Disease Control and Prevention (CDC), a U.S. government public health body, revealed that over one in seven American adults—roughly 35.5 million individuals or about 14%—were estimated to have chronic kidney disease in 2023, with nearly 90% of those affected remaining unaware. Consequently, the rising incidence of chronic kidney disease is fueling growth within the parathyroid disease treatment market.
Parathyroid Disease Treatment Market Segment Landscape: Which Areas Lead Market Development?
The parathyroid disease treatment market covered in this report is segmented –
1) By Treatment: Calcimimetics, Bisphosphonates, Plicamycin, Hormone Replacement Therapy, Other Treatments
2) By Route Of Administration: Oral, Parenteral
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
4) By End-Users: Hospitals, Homecare, Specialty Centers, Other End-Users
Subsegments:
1) By Calcimimetics: Cinacalcet, Etelcalcetide
2) By Bisphosphonates: Alendronate, Ibandronate, Risedronate, Zoledronic Acid
3) By Plicamycin: Mithramycin (Plicamycin) Monotherapy, Combination Therapies Involving Plicamycin
4) By Hormone Replacement Therapy: Estrogen Therapy, Progesterone Therapy, Combined Hormonal Therapies, Selective Estrogen Receptor Modulators (SERMs)
5) By Other Treatments: Parathyroid Hormone (PTH) Analogues, Surgery (Parathyroidectomy), Dietary Supplements, Lifestyle And Nutritional Interventions
Parathyroid Disease Treatment Market Trends Driving Strategic Industry Expansion
Key industry players in the parathyroid disease treatment market are prioritizing the creation of novel solutions like parathyroid hormone prodrugs, designed to enhance calcium regulation and lower the frequency of dosing for individuals with hypoparathyroidism. Prodrugs of parathyroid hormone (PTH) are inactive substances that transform into active PTH within the body, helping to maintain calcium and phosphate equilibrium. As an example, in August 2024, Ascendis Pharma A/S, a biopharmaceutical firm headquartered in Denmark, secured approval from the US Food and Drug Administration (FDA) for YORVIPATH (palopegteriparatide), a parathyroid hormone (PTH[1-34]) prodrug intended for managing chronic hypoparathyroidism in adults. This once-daily treatment ensures sustained parathyroid hormone activity throughout a 24-hour period, presenting an alternative to standard calcium and vitamin D supplementation by directly targeting the root hormone deficiency. The clearance of YORVIPATH highlights the growing focus on advanced hormone replacement approaches, aimed at boosting treatment compliance and achieving improved health results for those affected by parathyroid conditions.
Parathyroid Disease Treatment Market Industry Leaders And Market Competition
Major companies operating in the parathyroid disease treatment market are AstraZeneca PLC, Amgen Inc., Kyowa Kirin Co. Ltd., OPKO Health Inc., Septerna Inc., Entera Bio Ltd., Visen Pharmaceuticals (Shanghai) Co. Ltd., Ascendis Pharma A/S, Aeterna Zentaris Inc., MBX Biosciences Inc., Crinetics Pharmaceuticals Inc., Vidasym Inc., Rani Therapeutics LLC, Pathalys Pharma Inc.
Access The Complete Parathyroid Disease Treatment Market Report:
Parathyroid Disease Treatment Market Leading Geography: Which Region Generates The Most Revenue?
Asia-Pacific was the largest region in the parathyroid disease treatment market in 2025. The regions covered in the parathyroid disease treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model